Biotech IV Monitor

KOD — Kodiak Sciences Inc

$2.6B market cap · 3 upcoming readouts tracked

Clinical trial readout dates for Kodiak Sciences Inc, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is February 2027.

Next readoutFebruary 2027in ~3 months
Upcoming readouts33 Phase 3
Market cap$2.6B
Cash & investments$89M~1 quarters at last loss rate
Recent 8-K filings1latest 2026-11-12

Recently completed

The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.

Phase 3 Tarcocimab tedromer
Wet Age-related Macular Degeneration · NCT06556368
September 2026
Primary data collected

Upcoming readouts

Phase 3 KSI-101
Macular Edema Secondary to Inflammation · NCT06996080
February 2027
Recruiting
Phase 3 KSI-101
Macular Edema Secondary to Inflammation · NCT06990399
April 2027
Recruiting
Phase 3 Tabirafusp tedromer
Diabetic Macular Edema (DME) · NCT07734844
August 2028
Recruiting

Cash position

Kodiak Sciences Inc reported $89M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-12). Its net loss for that quarter was $66M; at that rate the cash would last about 1 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-12

Companies working on similar indications

Discussion

No messages yet. If you follow KOD, you can start the conversation.
Track KOD in real time
See live implied volatility for KOD and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on KOD
Contact — questions or corrections about KOD: dukeupt@gmail.com